Desidustat vs Molidustat

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Kidney Disease

Shared mechanism: HIF prolyl hydroxylase (HIF-PH1/2/3) · full Chronic Kidney Disease pipeline

Desidustat · Oxemia

Marketed by Zydus Lifesciences and partners

Phase 3 in Chronic Kidney Diseasesmall molecule
Partial signal

NCT04012957 · Phase 3 · completed

The study was randomized and used an active darbepoetin comparator, but it was open-label and its primary outcome was change in hemoglobin, a surrogate laboratory measure rather than a hard clinical or endoscopic outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Hemoglobin level (24 weeks): Change in hemoglobin baseline to week 16-24: desidustat +0.95 g/dL vs epoetin alfa +0.80 g/dL (difference 0.14 g/dL, 95% CI -0.13 to 0.42), met prespecified noninferiority margin; hemoglobin responders 59.22% desidustat vs 48.37% epoetin alfa (p=0.0382) (met)

Result source: NCT04215120

Molidustat

Marketed by Bayer

Phase 3 in Chronic Kidney Diseasesmall molecule
Partial signal

NCT03543657 · Phase 3 · completed

The trial randomized 229 participants to molidustat or darbepoetin alfa with matching placebos and quadruple blinding. Its primary endpoints were hemoglobin measures, which are laboratory surrogate outcomes. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

The mean Hb level during the evaluation period (From week 33 to 36); The change in mean Hb level during the evaluation period from baseline (Baseline and week 33 to 36): Mean Hb during evaluation period (weeks 33-36): molidustat 10.63 g/dL (95% CI 10.42-10.84) vs darbepoetin alfa 10.77 g/dL (95% CI 10.59-10.95); LS mean difference -0.13 g/dL (95% CI -0.46 to 0.19); noninferiority (margin 1.0 g/dL) established (met)

Result source: NCT03543657

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointDesidustatMolidustat
Kidney composite outcome—Not posted · NCT04012957—Not posted · NCT03350347
UACR, % change—Not posted · NCT04012957—Not posted · NCT03350347
eGFR slope—Not posted · NCT04012957—Not posted · NCT03350347
Haemoglobin, change1.9 vs 1.8avs darbepoetinNCT04012957
1 other result
—Not posted · NCT03350347

Kidney composite outcome

Desidustat
—Not posted · NCT04012957
Molidustat
—Not posted · NCT03350347

UACR, % change

Desidustat
—Not posted · NCT04012957
Molidustat
—Not posted · NCT03350347

eGFR slope

Desidustat
—Not posted · NCT04012957
Molidustat
—Not posted · NCT03350347

Haemoglobin, change

Desidustat
1.9 vs 1.8avs darbepoetinNCT04012957
1 other result
Molidustat
—Not posted · NCT03350347
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Desidustat

Hemoglobin Change g/dL 1.95 vs 1.83 darbepoetin g/dL
absolute change · g/dL
NCT04012957 · Phase 3 · sponsor-reported, not registry data
show 1 more result
0.95 vs 0.8 epoetin alfa g/dL
NCT04215120 · Phase 3 · sponsor-reported, not registry data
Hemoglobin 77.78% vs 68.48% darbepoetin
responder rate · % of participants
NCT04012957 · Phase 3 · sponsor-reported, not registry data
show 1 more result
59.22% vs 48.37% epoetin alfa
NCT04215120 · Phase 3 · sponsor-reported, not registry data

Molidustat

Hgb Target Range 54.9%
responder rate · % of participants
No placebo or comparator arm
NCT03418168 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Desidustat's landscape · Molidustat's landscape